Merck | MRK - Cash And Equivalent


Merck reported EUR2.74B in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
Adidas EUR 1.16B 286M Jun/2026
Adyen EUR 12.25B 1.82B Jun/2026
Akzo Nobel EUR 2.76B 1.14B Mar/2026
Alcon AG USD 1.58B 80M Mar/2026
Amadeus IT EUR 677.2M 298.4M Mar/2026
Amarin USD 143.56M 12.5M Jun/2026
AstraZeneca USD 4.89B 2.67B Jun/2026
BASF EUR 7.8B 4.71B Jun/2026
Bayer EUR 4.29B 1.44B Jun/2026
Beiersdorf EUR 1.2B 33M Dec/2025
Covestro EUR 648M 44M Dec/2025
Danone EUR 1.98B 364M Dec/2025
Fresenius EUR 2.06B 752M Mar/2026
Fresenius Medical Care EUR 1.06B 177.89M Jun/2026
Genmab DKK 1.5B 18M Jun/2026
Givaudan CHF 603M 3M Jun/2024
GlaxoSmithKline GBP 3.44B 292M Mar/2026
GRIFOLS EUR 513M 189M Jun/2026
Henkel EUR 2.71B 163M Dec/2025
Hikma Pharmaceutical USD 217M 19M Dec/2025
Infineon EUR 1.07B 232M Jun/2026
Lakefront Biotherapeutics EUR 135.95M 69.15M Jun/2026
Linde USD 3.96B 1.1B Mar/2026
Lonza CHF 719M 188M Dec/2025
Merck EUR 2.74B 415M Mar/2026
Novartis USD 7.62B 739M Jun/2026
Philips EUR 1.79B 803M Jun/2026
Roche Holding CHF 7.55B 579M Jun/2025
Sanofi EUR 6.35B 806M Jun/2026
UCB EUR 1.57B 1.14B Dec/2024